ZPRÁVA O PRŮBĚHU KLINICKÉHO HODNOCENÍ REMED (12. 2. 2021 – 11. 2. 2022)
| Title in English | REPORT ON THE PROGRESS OF THE REMED CLINICAL EVALUATION (February 12, 2021 – February 11, 2022) |
|---|---|
| Authors | |
| Year of publication | 2022 |
| MU Faculty or unit | |
| Web | REMED |
| Description | REMED is national, multicentre clinical trial carried out by the University Hospital Brno in cooperation with RI CZECRIN. The primary objective of the study is to test the hypothesis that administration of dexamethasone 20 mg daily is more effective with COVID-19 compared to a daily dose of dexamethasone 6 mg in adult patients with moderate or severe ARDS. During year 2021 was eight newsletters prepared and sent to clinical sites. |
| Related projects: |